Efficacy profiles
PD, SD
DISEASE
At the time of data cut-off (March 16, 2022), the median follow-up time was 12.1 months. Nine (47.4%) patients experienced PD and four (21.1%) died in the IP/IC plus camrelizumab group, with a median PFS of 10.25 (95% CI 9.40-NA) months. In the EP/EC plus PD-L1 group, 18 (52.9%) patients developed PD and six (17.6%) patients died, with a median PFS of 7.10 (95% CI 5.79-8.40) months. IP/IC plus camrelizumab showed better PFS than EP/EC plus PD-L1 as first-line treatment in patients with ES-SCLC (HR=0.58, 95% CI 0.42-0.81; Kaplan-Meier curves of progression-free survival.In the IP/IC plus camrelizumab group, 17 (89.5%) patients had PR, and two (10.5%) had SD, with a median DoR of 8.74 months. In the EP/EC plus PD-L1 inhibitor group, 28 (82.4%) patients had PR, four (11.8%) had SD, and two (5.9%) had PD. The median DoR was 4.4 months. The DCR and ORR were 100% and 89.6% in the IP/IC plus camrelizumab group, as well as 94.1% and 82.4% in the EP/EC plus PD-L1 inhibitor group, respectively (Treatment efficacy.EP/EC, (etoposide plus cisplatin, or etoposide plus carboplatin); IP/IC, (irinotecan plus cisplatin, or irinotecan plus carboplatin); PR, partial response; DoR, duration of response; SD, stable disease; PD, progression disease; DCR, disease control rate; ORR, objective response rate; PFS, progression-free survival.As of the last follow-up, 18 (53.9%) patients with EP/EC plus PD-L1 inhibitor and nine (47.4%) patients with IP/IC plus camrelizumab developed PD. Post-progression treatment was at the discretion of the investigator depending on the patient’s condition. Of these patients with PD in the EP/EC plus PD-L1 inhibitor group, eight (23.5%) patients subsequently started receiving PD-L1 inhibitor plus other chemotherapy regimens, one (2.9%) patient received topotecan, one (2.9%) patient received albumin paclitaxel monotherapy, and eight (53.9%) patients started receiving IP/IC plus PD-1 inhibitor. In the IP/IC plus camrelizumab group, four (10.5%) patients started treatment with EP/EC plus PD-L1 inhibitor (atezolizumab/durvalumab) following progression, four (10.5%) patients began EP/EC treatment, and one patient (5.3%) received anlotinib monotherapy.